摘要
1型糖尿病（type1 diabetes mellitus，T1DM）是一种以胰岛β细胞进行性损伤、胰岛素分泌绝对不足为基础的器官特异性自身免疫性疾病，终生皮下注射胰岛素仍为目前主要的治疗手段。但该治疗方法给患者带来巨大痛苦，且不能改善远期预后。随着现代医学的发展，医生可利用基因技术等综合手段，实现胰岛β细胞的再生与转化，尽可能保护T1DM患者残存胰岛β细胞功能，为防止T1DM急慢性并发症的发生提供了新的思路。目前有关胰岛β细胞重建的研究主要集中于胰岛移植、干细胞移植、免疫调节剂的应用等，但多因自身局限，不能满足临床需求。胰岛r细胞原位转化为胰岛素分泌细胞的研究，因其独特的优势，成为目前的研究热点。该文将对胰岛r细胞原位转化的技术手段、影响因素、可能机制等方面进行综述。
Type 1 diabetes mellitus （T1DM） is an organ-specific autoimmune disease caused by absolute lack of insulin secretion and progressive pancreatic β cell damage. Patients require lifelong subcutaneous injection of insulin. However, this treatment could induce great pain without improving long-term prognosis. Along with the medicine development, comprehensive methods including genetic technology are adopted to achieve pancreatic β cell regeneration and transformation. Protecting the function of remaining pancreatic β cells for T1 DM patients provides a new insight in prevention of acute and chronic T1DM complications. Currents studies of islet β cell reconstruction focus on islet transplantation, stem cell transplantation and immune regulator applications. Unfortunately, owing to their limitations, these methods cannot satisfy clinical application. While transdifferentiation of pancreatic islet δ cells has become a hope recently because of its unique advantages. In this paper, we will summarize the technical methods, influence factors and possible mechanisms of the transdifferentiation of pancreatic islet δ cells.
出处
《国际儿科学杂志》
2017年第2期108-111,共4页
International Journal of Pediatrics
基金
国家自然科学基金资助项目（81170762）
关键词
1型糖尿病
胰岛β细胞再生
基因治疗
Type 1 diabetes
Pancreatic β cell regeneration
Gene Therapy
